Alnylam Pharmaceuticals vs Bristol Myers Squibb
Alnylam Pharmaceuticals (ALNY) and Bristol Myers Squibb (BMY) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $19.3B
- Last close
- $143.82
- 12 months
- −67.7%
- Market value
- $120B
- Last close
- $58.80
- 12 months
- +28.0%
At a glance
- The biggest part of Alnylam Pharmaceuticals's revenue is AMVUTTRA (62%); at Bristol Myers Squibb it is Growth Portfolio (55%).
- By market value, Bristol Myers Squibb ($120.2B) is about 6.2 times Alnylam Pharmaceuticals ($19.3B).
- Over the last 12 months Alnylam Pharmaceuticals's share price moved −67.7% and Bristol Myers Squibb's +28.0%; against the S&P 500 that is −73.5 points and +22.3 points.
- In their last fiscal years Alnylam Pharmaceuticals kept 8.4% of revenue as net income and Bristol Myers Squibb 14.6%.
- In the last 90 days insiders reported 2 open-market purchases at Alnylam Pharmaceuticals and 0 at Bristol Myers Squibb; members of Congress disclosed 0 trades in Alnylam Pharmaceuticals and 0 in Bristol Myers Squibb.
- Next results: Alnylam Pharmaceuticals Feb 10, 2027, Bristol Myers Squibb Feb 3, 2027.
How each one makes money: Alnylam Pharmaceuticals revenue · Bristol Myers Squibb revenue
Share prices on one chart
Alnylam Pharmaceuticals and Bristol Myers Squibb, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Alnylam Pharmaceuticals ALNYNASDAQ · Pharmaceutical Preparations | Bristol Myers Squibb BMYNYSE · Pharmaceuticals | |
|---|---|---|
| Size and profitability | ||
| Market value | $19.3B | $120B |
| Revenue, last fiscal year | $3.71B | $48.2B |
| Net income, last fiscal year | $314M | $7.05B |
| Net marginNet income as a share of revenue | 8.4% | 14.6% |
| Free cash flow | $465M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Bristol Myers Squibb against
Common questions
How is Alnylam Pharmaceuticals different from Bristol Myers Squibb?
Alnylam Pharmaceuticals (ALNY) is in Pharmaceutical Preparations on NASDAQ, with $3.71B of revenue in its last fiscal year and a net margin of 8.4%. Bristol Myers Squibb (BMY) is in Pharmaceuticals on NYSE, with $48.2B of revenue in its last fiscal year and a net margin of 14.6%. The biggest part of Alnylam Pharmaceuticals's revenue is AMVUTTRA (62%); at Bristol Myers Squibb it is Growth Portfolio (55%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Alnylam Pharmaceuticals and Bristol Myers Squibb compare in size?
Bristol Myers Squibb has the larger market value: Alnylam Pharmaceuticals $19.3B and Bristol Myers Squibb $120B, at the last close.
Whose share price rose more over the last 12 months, ALNY or BMY?
Over the last 12 months Alnylam Pharmaceuticals moved −67.7% and Bristol Myers Squibb +28.0%. Past price moves say nothing about the future.
Which has had more insider buying, Alnylam Pharmaceuticals or Bristol Myers Squibb?
Since 2006, Bristol Myers Squibb insiders reported 47 open-market purchases against 37 for Alnylam Pharmaceuticals. These are counts of what was filed, not a view on either stock.
Do members of Congress trade ALNY or BMY?
In the last 12 months, members of Congress disclosed 0 trades in Alnylam Pharmaceuticals (ALNY) and 8 in Bristol Myers Squibb (BMY).
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Alnylam Pharmaceuticals pageBristol Myers Squibb pageRare insider trades this weekAll comparisons
https://oqro.io/compare/alny-vs-bmy







